Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Melanotan-I

Afamelanotide, MT-I, [Nle4-D-Phe7]-α-MSH, Scenesse, CUV-1647

Quick Stats
Studies 225
Trials 100
Score 2
2003 pubmed

Functional characterization of melanocortin-4 receptor mutations associated with childhood obesity.

Tao. Ya-Xiong YX; Segaloff. Deborah L DL

Key Findings

  • Four mutations (S58C, N62S, Y157S, C271Y) showed reduced ligand binding and lower cAMP signaling.
  • Two mutations (P78L, G98R) showed no detectable ligand binding at all.
  • Five mutations (D37V, P48S, V50M, I170V, N274S) behaved like the wild‑type receptor, with normal surface expression, binding, and signaling.
  • Impaired mutants were trapped inside cells, explaining their reduced surface expression.

Practical Outcomes

  • If you plan to use melanotan‑I (an alpha‑MSH analog) for weight or metabolic effects, your personal MC4R genetics could influence how well it works. People with loss‑of‑function MC4R variants might see little benefit, while those with normal‑function variants could respond as expected. Genetic testing could help personalize dosing, but the study itself doesn’t provide dosage guidelines.

Summary

Scientists looked at 11 genetic variants of the MC4R receptor that are linked to severe childhood obesity. They found that some variants can't bind the hormone (or drug) well and don't trigger the usual cell signals, while other variants work just like the normal receptor. This shows that not all MC4R mutations cause functional problems.

Abstract

The melanocortin-4 receptor (MC4R) is a member of the rhodopsin-like G protein-coupled receptor family. The binding of alpha-MSH to the MC4R leads to increased cAMP production. Recent pharmacological and genetic studies have provided compelling evidence that MC4R is an important regulator of food intake and energy homeostasis. Allelic variants of MC4R were reported in some children with early-onset severe obesity. However, few studies have been performed to confirm that these allelic variants result in an impairment of the receptor's function. In this study, we expressed wild-type and variant MC4Rs in HEK293 cells and systematically studied ligand binding, agonist-stimulated cAMP, and cell surface expression. Six of the 11 mutants examined had either decreased (S58C, N62S, Y157S, C271Y) or no (P78L, G98R) ligand binding, with proportional impairments in [Nle4, d-Phe7]-alpha-MSH-stimulated cAMP production. Confocal microscopy confirmed that the observed decreases in hormone binding by these mutants are associated with decreased cell surface expression due to intracellular retention of the mutants. The other five allelic variants (D37V, P48S, V50M, I170V, N274S) were found to be expressed at the cell surface and to bind agonist and respond with increased cAMP production normally. The data on these latter five variants raise the question as to whether they are indeed causative of the obesity or not and, if so, by what mechanism. Our data, therefore, stress the importance of characterizing the properties of MC4R variants associated with early-onset severe obesity. We further propose a classification scheme for mutant MC4Rs based upon their properties.

Study Information

Provider

pubmed

Year

2003

Date

2003-06-19T00:00:00.000Z

DOI

10.1210/en.2003-0524